HYTN Innovations

What HYTN Innovations does

HYTN Innovations Inc. is a Vancouver-headquartered, publicly traded (CSE: HYTN) GMP-certified pharmaceutical manufacturer specializing in the formulation, manufacturing, marketing, and sale of products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids and psilocybin mushrooms. The company operates a purpose-built GMP manufacturing facility in Kelowna, British Columbia, with capabilities spanning bulk processing, API fabrication, finished dosage form production, and packaging across multiple formats (jars, bags, 510 vape cartridges, 1g sachets). HYTN holds a Health Canada Drug Establishment Licence, Cannabis Drug Licence, Controlled Drugs and Substances Dealers Licence, and PIC/S GMP certificates recognized by the EU, UK, Australia, US, Bermuda, and Israel, positioning it among a limited number of globally certified manufacturers for non-sterile cannabinoid and psilocybin APIs and finished products.

The company's product portfolio is anchored by two proprietary technology platforms: Elevation Technology, a registered trademark nano-emulsification system that creates stable sub-80nm droplets for improved bioavailability of lipophilic actives and the generation of patentable Novel Chemical Entities; and HARd (Hermetic Autogenous Remediation), a non-irradiation microbial remediation process for dried cannabis flower. HYTN manufactures GMP-certified cannabis APIs (live resin, bulk dry flower, solventless extraction) and finished goods, GMP psilocybin mushroom products (one of few globally certified sites), and consumer packaged goods including sugar-free sparkling cannabis beverages and nano drops through its Summit partnership. The company is also pursuing a BPC-157 peptide drug development program for refractory ligament disorders, proposed for spin-out into a separate CSE-listed entity (SpinCo).

HYTN's revenue model is a hybrid of direct GMP product sales (one-time product sales to international pharmaceutical distributors and retailers), contract manufacturing services (CDMO engagements with biotech and cannabis companies under manufacturing agreements), and consumer packaged goods (provincial retailer distribution in Canada). International distribution is channeled through named enterprise partners including SNDL Inc. (NASDAQ: SNDL), 4C Labs (UK), and A1 Cannabis (Summit Beverages), with HYTN serving federally regulated medical cannabis markets in Germany, the UK, and Australia. The company has 11-50 employees and is in early commercial scale-up, with first full commercial international batch shipments occurring in 2026.

Name

HYTN Innovations

Legal name

HYTN Innovations Inc.

Website

https://hytn.ca

Company type

Public

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

HYTN Innovations is a GMP-certified Canadian pharmaceutical manufacturer (CSE: HYTN) producing cannabis APIs, psilocybin mushroom products, and consumer cannabis beverages for international regulated medical markets including Germany, UK, and Australia, leveraging proprietary Elevation Technology and HARd processes.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Cannabis Accessories & Ancillary Products Wholesale (Vapes, Packaging, Hardware) (CRAOAIAH)

Keywords

• GMP pharmaceutical manufacturing
• Cannabis API fabrication
• Psilocybin mushroom processing
• Contract drug manufacturing
• Cannabis consumer beverages

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. GMP Cannabis Product Sales: HYTN manufactures and sells GMP-certified cannabis products (dried flower, extracts, vape cartridges, live resin) as finished goods or bulk APIs to international pharmaceutical and medical cannabis markets including Germany, UK, and Australia. Revenue is generated through direct commercial batch shipments, wholesale product releases, and reorder cycles.
2. Contract Manufacturing Services: HYTN provides GMP contract manufacturing services for third-party partners (SNDL, A1 Cannabis) including processing of bulk and finished cannabis products under EU GMP standards. Compensation structured through manufacturing agreements, pricing agreements, and purchase orders, with revenue recognized upon delivery of processed products and export clearance.
3. GMP Processing Services (HARd): HYTN offers its proprietary HARd (Hermetic Autogenous Remediation) microbial remediation service to domestic and international counterparties seeking remediation solutions within EU-GMP-aligned quality frameworks. Engagements assessed on a program-by-program basis including technical fit, quality requirements, commercial terms, and applicable regulatory framework.
4. Cannabis Consumer Packaged Goods: HYTN manufactures and sells consumer cannabis products including cannabis-infused nano emulsions, beverages (sparkling), edibles, and dry flower. Products are sold to provincially and territorially authorized retailers in Canada following the company's license amendment for sale of cannabis extract, edible cannabis, and cannabis topical products. Revenue from Summit brand beverages through A1 Cannabis partnership via revenue-sharing agreement.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

HYTN Innovations is a GMP-certified pharmaceutical manufacturer that formulates, fabricates, packages, and labels non-sterile Active Pharmaceutical Ingredients (APIs) and finished dosage forms containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids and psilocybin mushrooms. The company sells these APIs and finished goods (dried flower, vape cartridges, pharmaceutical oils, psilocybin mushroom products) to international pharmaceutical distributors and medical cannabis markets in Germany, the UK, and Australia, and also produces consumer cannabis beverages, nano drops, and edibles sold through Canadian provincial retailers. Operations are enabled by two proprietary technology platforms, Elevation Technology® and HARd (Hermetic Autogenous Remediation™).

Product overview

HYTN Innovations Inc. is a pharmaceutical manufacturer specializing in the formulation, manufacturing, marketing, and sale of products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids and psilocybin. The company operates as a platform of GMP-certified manufacturing services and consumer/prescription products. Its core offerings include: GMP Cannabis Processing (bulk and finished packaged goods), GMP Active Pharmaceutical Ingredient (API) Fabrication (including Live Resin API, Dry Flower API, and Psilocybin Mushroom API), GMP Psilocybin Mushroom Manufacturing, and Cannabis Consumer Packaged Goods (nano emulsions, beverages, edibles). Supporting the product portfolio are two proprietary technology platforms: Elevation Technology® (a nano-emulsification system creating clear, stable, bioavailable cannabinoid formulations used in consumer products and positioned for NCE generation) and HARd (Hermetic Autogenous Remediation, a proprietary microbial remediation process for dried cannabis flower). The company also operates a BPC-157 peptide drug development program (proposed spin-out as SpinCo) and holds the necessary regulatory infrastructure to manufacture prescription pharmaceutical products. HYTN serves federally regulated international markets including Germany, the United Kingdom, Australia, and the United States.

Differentiator

Problem solved

Functional benefit

Brands

• Elevation Technology: Proprietary nano-emulsification technology creating clear, odorless emulsions for cannabis products with enhanced bioavailability and rapid onset.

Products and services

• GMP Cannabis Processing GMP-certified processing of cannabis products including final packaged goods (jars and bags), bulk packaging of dry cannabis flower, solventless extract manufacture, and cannabis vape manufacturing (510 cartridge). Production capacity of 15 kg per shift for finished goods packaging and 75 kg per shift for bulk dry cannabis flower packaging. Offered to international pharmaceutical distributors and Canadian provincial retailers.
• GMP Active Pharmaceutical Ingredient (API) Fabrication Fabrication of Active Pharmaceutical Ingredients (APIs) including Live Resin API, Bulk Dry Flower API, Bulk Dry Psilocybin Mushroom API, and Bulk Solventless Extraction API. Authorized under Health Canada Drug Establishment Licence for non-sterile APIs in solid and non-solid forms. Offered to pharmaceutical sponsors, biotech companies, and clinical-stage drug developers.
• GMP Psilocybin Mushroom Manufacturing GMP-certified cultivation, processing, and release of psilocybin mushrooms, including final packaged goods in 1g sachets and bulk packaging. Among the global few GMP-certified sites for psilocybin mushroom manufacturing. Production capacity of 5 kg per shift for finished psilocybin mushroom goods packaging. Offered to clinical research programs, pharmaceutical sponsors, and regulated psychedelic therapy markets.
• Cannabis Consumer Packaged Goods Consumer cannabis products including nano emulsions, sparkling beverages (5mg and 10mg THC), 100mg Nano Shots, edibles, dry flower processing, and non-solid extracts. Sold under Summit brand via A1 Cannabis partnership through Canadian provincial and territorial authorized retailers. Production capacity of 6,000 units per shift for active ingredient infused beverages and 10,000 units per shift for active ingredient infused edibles, with active emulsion capacity of 50 mg/ml at 400 L per shift.
• Cannabis Nano Drops Cannabis-infused nano-emulsified THC drops (100mg) formulated using Elevation Technology® for rapid onset and predictable effects. Sold through Canadian provincial and territorial authorized retailers under the Summit brand.
• Cannabis Sparkling Beverages

Quantifiable outcome

• Multi-log reductions in Total Aerobic Microbial Count, Total Yeasts and Moulds Count, and Bile-Tolerant Gram-Negative organisms demonstrated through HARd validation work and third-party analytical testing
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered supporting and core.

• MCS Market Communication Service GmbHsupportingGTM or Marketing Partner · 24 April 2026HYTN extended its engagement with Germany-based MCS Market Communication Service GmbH to provide marketing and communications services including digital content creation, advertising materials, keyword optimization, project coordination, and media distribution. The 60-day engagement commencing April 24, 2026, costs €100,000 and targets investor audiences through online platforms using demographic, geographic, keyword, and interest-based targeting. This was the third extension of the engagement following initial engagement in January 2026 and extensions in March and April 2026.
• Klonetics Plant Science Inc.supportingStrategic or Co-development Partner · 28 March 2025HYTN entered into strategic supply agreement with Klonetics Plant Science Inc., a cannabis cultivator, following comprehensive vendor qualification including site audits, quality control evaluations, and GACP compliance verification. Klonetics was qualified under HYTN's GMP system for the German market, producing high-potency cultivars specifically tailored for German patient needs. The agreement establishes strict product specifications, testing protocols, and pricing structures ensuring compliance with German pharmacopeia standards and non-irradiation requirements.
• A1 Cannabis Inc. (Summit Cannabis Beverages)coreStrategic or Co-development Partner · 17 February 2025HYTN entered into comprehensive collaboration agreements with A1 Cannabis Inc. (owner of Summit Cannabis Beverages) consisting of a manufacturing agreement, consulting agreement, and letter of understanding with a three-year term. A1 transitioned its complete cannabis product portfolio (5 mg and 10 mg Sparkling Beverages, 100 mg Nano Shots under Summit brand) from Tilray Brands to HYTN. A1 CEO Cole Miller oversees HYTN's domestic product sales forecasting, product development, and sales management with compensation structured as a revenue-sharing agreement for all A1/Summit-branded products. HYTN registers, manufactures, collects revenues, and sells A1 products under its own licenses while A1 retains brand and IP rights. This is not a joint venture.
• SNDL Inc.coreStrategic or Co-development Partner · 10 January 2025HYTN entered into manufacturing and pricing agreements with SNDL Inc. (NASDAQ: SNDL), one of the world's largest vertically integrated cannabis companies, to process both bulk and finished cannabis products under EU GMP for international markets including UK, Germany, and Australia. SNDL provides specialized equipment, cannabis consumables, and required capital, while HYTN provides GMP-certified manufacturing capabilities. The two-year agreement was signed August 2024 with an initial purchase order for EU GMP-certified dried cannabis flower featuring multiple cultivars for export to the UK. HYTN also collaborated with SNDL on GMP-compliant vape cartridge development under a separate agreement signed January 17, 2025.
• 4C LabscoreChannel Partner/ Reseller/ Distributor · 10 September 2024HYTN established international manufacturing and pricing agreements with 4C Labs, a leading UK importer and distributor of cannabis-based pharmaceuticals. HYTN received opening orders and import permits from 4C Labs in November 2024 and successfully exported and released GMP cannabis products to 4C Labs in the UK in December 2024. This partnership represents HYTN's first international commercial shipment under its GMP designation.

Scale indicators13 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• MediPharm Labs: Canadian GMP-certified cannabis pharmaceutical manufacturer focused on cannabinoid APIs, finished dose formats, and international export. Closely comparable to HYTN in business model (CDMO + branded derivatives), target markets (Germany, Australia, LATAM), and regulatory positioning (GMP, Drug Establishment Licence).
• Valens GroWorks: Canadian cannabis extraction and white-label manufacturer producing cannabinoid oils, vapes, beverages, and topicals for medical and recreational markets. Comparable to HYTN as a Canadian cannabis CDMO/CPG manufacturer serving both wholesale and branded consumer channels.

Broad incumbents

• OrganiGram Holdings: Major Canadian licensed cannabis producer with GMP-aligned manufacturing and international medical cannabis exports. Comparable to HYTN as a federally regulated Canadian cannabis operator with international ambitions, though substantially larger and more vertically integrated.
• Tilray Brands: Global cannabis and consumer packaged goods company with GMP manufacturing and worldwide distribution including beverages. Comparable to HYTN in GMP cannabis processing and beverage manufacturing, and was the prior contract manufacturer for the Summit brand now at HYTN.
• Aurora Cannabis: Large Canadian cannabis producer with EU GMP-certified facilities and international medical cannabis distribution across Germany and other European markets. Comparable to HYTN in pursuing GMP-certified supply into Germany and other regulated international pharmaceutical markets.
• Canopy Growth: Major Canadian cannabis company with GMP manufacturing capabilities and global medical cannabis operations including Germany. Comparable to HYTN in Canadian GMP cannabis manufacturing and European medical cannabis positioning, though at significantly larger scale.
• Jazz Pharmaceuticals: Commercial-stage pharmaceutical company marketing Epidiolex, an FDA- and EMA-approved CBD prescription drug generating $972.4M in 2024 net product sales at 88.2% gross margin. Comparable to HYTN as the established commercial benchmark for cannabinoid-derived prescription pharmaceuticals that HYTN's GMP API franchise ultimately targets.

Emerging players

• Compass Pathways: Clinical-stage psychedelic therapy company developing COMP360 psilocybin therapy. Comparable to HYTN in targeting GMP-grade psilocybin supply for clinical and regulated therapeutic use, though Compass is a therapy sponsor rather than a manufacturer.
• ATAI Life Sciences: Clinical-stage biopharmaceutical platform developing psychedelic and other mental health therapies. Comparable to HYTN in addressing regulated psychedelic compound manufacturing and clinical supply, with partial overlap on GMP-grade psilocybin.
• GH Research: Clinical-stage company developing mebufotenin (5-MeO-DMT) therapies for depression, requiring GMP psychedelic APIs. Comparable to HYTN as a potential customer/peer in the GMP psychedelic API supply space for clinical-stage psychedelic therapy sponsors.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/hytnlife
• Facebookfacebook.com/HYTN.LIFE

Compliance18 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HYTN Innovations